ABOUT AVIDITY
Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution.
Avidity Biosciences Announces Presentations at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2020 /PRNewswire/ — Avidity Biosciences (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today that Sarah Boyce, Avidity’s President and CEO, will present a company overview at two upcoming investor conferences:
- 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:30 pm ET at the Lotte New York Palace Hotel
- 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 2:30 pm ET at the Boston Marriott Copley Place Hotel
About Avidity Biosciences
Avidity Biosciences, Inc. is a privately-held biotech company pioneering Antibody-Oligonucleotide Conjugates (AOC™) for treatment of rare muscle disorders and other serious diseases. AOCs combine the tissue selectivity of monoclonal antibodies and the specificity of oligonucleotide-based therapeutics to enable more effective targeting of tissues, such as skeletal muscle, immune cells, and heart to create a pipeline of targeted oligonucleotide therapeutics. The company’s lead research program addresses myotonic dystrophy type I, a disease with no approved treatment options. In April 2019, Avidity Biosciences and Eli Lilly announced a strategic partnership to utilize Avidity’s AOC technology to pursue therapeutic targets initially focused on immunology and other indications. For more information, please visit www.aviditybio.com.
Contacts:
Company:
Leslie Ann Kerins
(858) 401-7900
leslie@aviditybio.com
Media and Investors:
Amy Conrad
Juniper Point
858-366-3243
amy@juniper-point.com